Changeflow GovPing Healthcare & Life Sciences MAPT Targeting Oligonucleotides for Neurodegene...
Routine Rule Added Draft

MAPT Targeting Oligonucleotides for Neurodegenerative Disease Treatment

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

USPTO published patent application US20260109982A1 on April 23, 2026, filed September 24, 2025 (application no. 19338285), disclosing novel MAPT targeting sequences and MAPT targeting oligonucleotides for the treatment of neurodegenerative diseases. Four inventors are named: Anastasia Khvorova, Chantal Ferguson, Sarah Davis, and Kathryn Monopoli. The CPC classifications indicate this is a biotechnology/pharmaceutical invention (C12N 15/113, A61P 25/28).

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 258 changes logged to date.

What changed

USPTO published application US20260109982A1 disclosing MAPT targeting oligonucleotides for neurodegenerative disease treatment, naming four inventors: Anastasia Khvorova, Chantal Ferguson, Sarah Davis, and Kathryn Monopoli. The application (no. 19338285) was filed September 24, 2025 and published April 23, 2026. CPC classifications C12N 15/113 and A61P 25/28 indicate a biotechnology/central nervous system therapeutic invention.

Parties interested in RNAi, antisense, or neurodegenerative disease therapeutics should monitor this application's prosecution for competitive intelligence. A published patent application does not yet confer enforceable IP rights; patentability and claim scope will be determined during examination.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

OLIGONUCLEOTIDES FOR MAPT MODULATION

Application US20260109982A1 Kind: A1 Apr 23, 2026

Inventors

Anastasia Khvorova, Chantal Ferguson, Sarah Davis, Kathryn Monopoli

Abstract

This disclosure relates to novel MAPT targeting sequences. Novel MAPT targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.

CPC Classifications

C12N 15/113 A61K 31/00 A61K 31/7088 A61P 25/28 C12N 15/64 C12N 2310/14 C12N 2310/315 C12N 2310/321 C12N 2310/345 C12N 2310/351 C12N 2310/52 C12N 2320/32

Filing Date

2025-09-24

Application No.

19338285

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Draft
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Biotechnology firms
Industry sector
5417 Scientific Research
Activity scope
Gene therapy research Neurodegenerative disease treatment
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!